Related Experiment Video
Updated: Dec 29, 2025

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis
Priya R Soni1, Magali Noval Rivas1,2, Moshe Arditi3,4,5
1Division of Pediatric Infectious Diseases and Immunology; Burns and Allen Research Institute, Cedars-Sinai Medical Center and David Geffen School of Medicine at UCLA, Los Angeles, CA, 90048, USA.
Purpose Of The Review:
Kawasaki disease (KD) is a childhood systemic vasculitis of unknown etiology that causes coronary artery aneurysms (CAA), and if left undiagnosed can result in long-term cardiovascular complications and adult cardiac disease. Up to 20% of KD children fail to respond to IVIG, the mainstay of therapy, highlighting the need for novel therapeutic strategies. Here we review the latest findings in the field regarding specific etiology, genetic associations, and advancements in treatment strategies to prevent coronary aneurysms.
Recent Findings:
Recent discoveries using the Lactobacillus casei cell wall extract (LCWE)-induced KD vasculitis mouse model have accelerated the study of KD pathophysiology and have advanced treatment strategies including clinical trials for IL-1R antagonist, Anakinra. KD remains an elusive pediatric vasculitis syndrome and is the leading cause of acquired heart disease among children in the USA and developed countries. Advancements in combination treatment for refractory KD with further understanding of novel genetic risk factors serve as a solid foundation for future research endeavors in the field.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Endocarditis III: Medical Management
